Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.55 |
| ▸ | WNT3A | P56704 | 4/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508072 | 0.89 | HTR7 (0.64) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL29153730 | 0.86 | HSD17B3 (0.57) | CES2CES1CTNNB1WNT3AHPGD | |
| SCHEMBL633161 | 0.85 | CES2 (0.61) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL7959814 | 0.84 | CTNNB1 (0.57) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL634160 | 0.83 | CES2 (0.59) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL5954123 | 0.82 | CTNNB1 (0.49) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL4496569 | 0.81 | PARP1 (0.58) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL29649064 | 0.81 | CES2 (0.57) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL960252 | 0.81 | CES2 (0.57) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL2691520 | 0.81 | NR4A2 (0.62) | CES2CES1CTNNB1WNT3APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-1569917-B1 | PYRAZINE-BASED TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-12-07 | — | — | EP | disclosed |
| EP-1569917-B1 | PYRAZINE-BASED TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-12-07 | — | — | EP | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| EP-1689715-B1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2011-02-09 | — | — | EP | disclosed |
| EP-2277865-A1 | Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors | YM BioSciences Australia Pty Ltd (AU) | 2011-01-26 | — | — | EP | disclosed |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | TUBB1, TUBA1C, TUBB | CES2 2216/4885CES1 2358/4885CTNNB1 898/4885 |
| US-20160031835-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CES2 3664/4885CES1 3688/4885CTNNB1 3097/4885 |
| US-20080194583-A1 | Tubulin Inhibitors | TUBB1, TUBB3, TUBA1C | CES2 3782/4885CES1 3826/4885CTNNB1 3090/4885 |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | CES2 2462/4885CES1 1968/4885CTNNB1 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.